Analysts predict that Axsome Therapeutics Inc (NASDAQ:AXSM) will report earnings of ($0.31) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Axsome Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.35) and the highest estimate coming in at ($0.27). Axsome Therapeutics reported earnings of ($0.19) per share during the same quarter last year, which suggests a negative year over year growth rate of 63.2%. The firm is scheduled to report its next earnings report on Tuesday, May 14th.
On average, analysts expect that Axsome Therapeutics will report full year earnings of ($1.13) per share for the current fiscal year, with EPS estimates ranging from ($1.27) to ($1.00). For the next financial year, analysts forecast that the business will post earnings of ($1.04) per share, with EPS estimates ranging from ($1.55) to ($0.77). Zacks’ earnings per share calculations are an average based on a survey of research firms that that provide coverage for Axsome Therapeutics.
Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Thursday, March 14th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.01.
A number of analysts recently commented on AXSM shares. ValuEngine lowered Axsome Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. HC Wainwright lifted their price objective on Axsome Therapeutics to $15.00 and gave the stock a “buy” rating in a research report on Monday, January 7th. LADENBURG THALM/SH SH reiterated a “positive” rating and issued a $45.00 price objective (up from $34.00) on shares of Axsome Therapeutics in a research report on Monday, January 7th. BTIG Research lifted their price objective on Axsome Therapeutics to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, January 8th. Finally, Zacks Investment Research lowered Axsome Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, January 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $28.00.
Axsome Therapeutics stock opened at $15.48 on Friday. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 3.86. Axsome Therapeutics has a 12-month low of $1.94 and a 12-month high of $16.80.
In other news, Director Mark Coleman acquired 5,100 shares of the stock in a transaction that occurred on Tuesday, March 19th. The stock was purchased at an average cost of $12.18 per share, for a total transaction of $62,118.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Nick Pizzie acquired 5,400 shares of the stock in a transaction that occurred on Tuesday, March 19th. The stock was purchased at an average price of $12.58 per share, with a total value of $67,932.00. Following the completion of the transaction, the chief financial officer now owns 36,340 shares of the company’s stock, valued at $457,157.20. The disclosure for this purchase can be found here. 34.30% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the company. Barclays PLC acquired a new position in shares of Axsome Therapeutics during the 4th quarter worth about $30,000. Bank of New York Mellon Corp acquired a new position in shares of Axsome Therapeutics during the 4th quarter worth about $98,000. Worth Venture Partners LLC acquired a new position in shares of Axsome Therapeutics during the 3rd quarter worth about $138,000. BlackRock Inc. grew its position in shares of Axsome Therapeutics by 14.6% during the 4th quarter. BlackRock Inc. now owns 64,049 shares of the company’s stock worth $181,000 after buying an additional 8,137 shares during the period. Finally, Tibra Equities Europe Ltd acquired a new position in shares of Axsome Therapeutics during the 1st quarter worth about $319,000. Institutional investors own 11.57% of the company’s stock.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.
Further Reading: Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.